\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPF	ROVAL
OMB Number:	3235-0287
Estimated average bu	ırden
	0.5

Estimated average burden	
hours per response:	0.5

DUGGAN ROBERT W		n*	2. Issuer Name and Ticker or Trading Symbol <u>Pulse Biosciences, Inc.</u> [PLSE]		ionship of Reporting F all applicable) Director	Persor	n(s) to Issuer 10% Owner
		(<i>'</i> ,	3. Date of Earliest Transaction (Month/Day/Year) 04/17/2017		Officer (give title below)		Other (specify below)
(Street) CLEARWATER	FL	33756	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	dual or Joint/Group F Form filed by One R Form filed by More t Person	eport	ng Person
(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)	
Common Stock	04/17/2017		Р		22,900	A	\$23.152 ⁽¹⁾	2,601,850	D		
Common Stock	04/17/2017		Р		10,500	A	\$24.342(2)	2,612,350	D		
Common Stock	04/17/2017		Р		73,900	A	\$25.388 ⁽³⁾	2,686,250	D		
Common Stock	04/18/2017		Р		33,819	A	\$25.058 ⁽⁴⁾	2,720,069	D		
Common Stock	04/18/2017		Р		28,000	A	\$26.021(5)	2,748,069	D		
Common Stock	04/19/2017		Р		32,990	A	\$22.235(6)	2,781,059	D		
Common Stock	04/19/2017		Р		53,228	A	\$23.284(7)	2,834,287	D		
Common Stock	04/19/2017		Р		26,000	A	\$24.348(8)	2,860,287	D		
Common Stock	04/19/2017		Р		37,905	A	\$25.374 ⁽⁹⁾	2,898,192	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of E		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. This is the weighted average purchase price of the shares, which ranged from \$22.925 to \$23.913 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

2. This is the weighted average purchase price of the shares, which ranged from \$23.97 to \$24.918 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

3. This is the weighted average purchase price of the shares, which ranged from \$24.982 to \$25.815 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

4. This is the weighted average purchase price of the shares, which ranged from \$24.66 to \$25.65 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

5. This is the weighted average purchase price of the shares, which ranged from \$25.75 to \$26.651 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

6. This is the weighted average purchase price of the shares, which ranged from \$21.835 to \$22.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

7. This is the weighted average purchase price of the shares, which ranged from \$22.84 to \$23.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

8. This is the weighted average purchase price of the shares, which ranged from \$23.966 to \$24.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

9. This is the weighted average purchase price of the shares, which ranged from \$25.134 to \$25.90 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

Remarks:

Brian Dow, as Attorney-in-Fact 04/19/2017 for Robert W. Duggan

** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.